Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KRISH PATEL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1346484821
CMS profile
430197
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$107,302.76

101 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KRISH PATEL

NPI 1346484821 · CMS profile ID 430197

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346484821?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KRISH PATEL, NPI 1346484821, CMS profile ID 430197. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346484821?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). KRISH PATEL, NPI 1346484821, CMS profile ID 430197. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346484821?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
KRISH PATEL, NPI 1346484821, CMS profile ID 430197, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1346484821?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

101 matching records · $107,302.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 101 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–101 of 101.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $1,340.0001/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141773234 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $98,999.63 120
PY2020 $62,915.66 48
PY2021 $70,051.36 53
PY2022 $63,355.09 61
PY2023 $77,594.58 85
PY2024 $107,302.76 101
PY2025 $50,717.96 132

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,326.59 4
PY2025 Principal investigator $1,096,951.53 61
PY2024 Principal investigator $2,837,665.11 238
PY2023 Recipient $1,600.00 3
PY2023 Principal investigator $2,255,623.12 182
PY2022 Recipient $1,880.00 2
PY2022 Principal investigator $2,058,436.91 98
PY2021 Principal investigator $1,704,415.97 132
PY2020 Principal investigator $2,628,950.77 126
PY2019 Recipient $476.00 1
PY2019 Principal investigator $1,071,506.45 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

65 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,300.00 12/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319088
Principal investigator 1 Janssen Research & Development, LLC $2,316.00 12/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319613
Principal investigator 1 Janssen Research & Development, LLC $14,436.00 12/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322390
Principal investigator 1 Janssen Research & Development, LLC $5,750.00 12/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323250
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323368
Principal investigator 1 Janssen Research & Development, LLC $4,795.00 12/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325102
Principal investigator 1 Janssen Research & Development, LLC $4,600.00 12/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175326452
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321443
Principal investigator 1 Janssen Research & Development, LLC $67,696.00 12/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321709
Principal investigator 1 PFIZER INC. $15,000.00 12/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1B OPENLABEL STUDY OF MAPLIRPACEPT IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN ADULT PARTICIPANTS WITH NONHODGKIN LYMPHOMA No dispute reported 06/30/2026 1228745491
Principal investigator 1 F. Hoffmann-La Roche AG $18,701.10 12/17/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Ph 1b of mosunetuzumab combined with lenalidomide in relapsed or refractory follicular lymphoma No dispute reported 06/30/2026 1211556525
Principal investigator 1 F. Hoffmann-La Roche AG $13,108.00 12/10/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Ph 1b of mosunetuzumab combined with lenalidomide in relapsed or refractory follicular lymphoma No dispute reported 06/30/2026 1211556529
Recipient F. Hoffmann-La Roche AG $875.67 12/09/2025 Covered Recipient Physician Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs) No dispute reported 06/30/2026 1211537272
Recipient F. Hoffmann-La Roche AG $875.67 12/09/2025 Covered Recipient Physician Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs) No dispute reported 06/30/2026 1211537275
Recipient F. Hoffmann-La Roche AG $1.00 12/09/2025 Covered Recipient Physician Diverse Preferences for Treatment Options in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Survey Results from Patients in the United States (US) No dispute reported 06/30/2026 1211537279
Recipient F. Hoffmann-La Roche AG $2,574.25 12/09/2025 Covered Recipient Physician Diverse Preferences for Treatment Options in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Survey Results from Patients in the United States (US) No dispute reported 06/30/2026 1211537283
Principal investigator 1 Kite Pharma, Inc. $21,648.78 11/21/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) No dispute reported 06/30/2026 1212068571
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321656
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175326185
Principal investigator 1 Janssen Research & Development, LLC $7,218.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175326350
Principal investigator 1 Janssen Research & Development, LLC $10,250.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320655
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321507
Principal investigator 1 PFIZER INC. $23,678.69 11/01/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228728215
Principal investigator 1 PFIZER INC. $9,558.22 10/31/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228722596
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $634.35 10/27/2025 Non-covered Recipient Entity
Scri Oncology Partners
A study of lisocabtagene maraleucel as firstline therapy for primary central nervous system lymphoma in patients who are not eligible for transplant No dispute reported 06/30/2026 1235993745
Principal investigator 1 ABBVIE INC. $3,500.00 10/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin s Lymphoma No dispute reported 06/30/2026 1202518197
Principal investigator 1 ABBVIE INC. $5,000.00 10/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin s Lymphoma No dispute reported 06/30/2026 1202518045
Principal investigator 1 ABBVIE INC. $14,500.00 10/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin s Lymphoma No dispute reported 06/30/2026 1202518047
Principal investigator 1 ABBVIE INC. $6,400.00 10/10/2025 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202422212
Principal investigator 1 Celgene Corporation $20,000.00 10/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1222305642
Principal investigator 1 Janssen Research & Development, LLC $26,427.00 10/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175326610
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,750.00 09/30/2025 Non-covered Recipient Entity
SCRI ONCOLOGY PARTNERS
A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1185552349
Principal investigator 1 PFIZER INC. $101,043.11 09/23/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228759240
Principal investigator 1 PFIZER INC. $20,637.39 09/10/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228754111
Principal investigator 1 Janssen Research & Development, LLC $4,856.00 08/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320687
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175320365
Principal investigator 1 Janssen Research & Development, LLC $5,750.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321893
Principal investigator 1 Janssen Research & Development, LLC $2,822.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175322699
Principal investigator 1 PFIZER INC. $23,679.67 08/01/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228767878
Principal investigator 1 Janssen Research & Development, LLC $7,218.00 07/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175319081
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 07/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323124
Principal investigator 1 Kite Pharma, Inc. $1,300.00 07/28/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7) No dispute reported 06/30/2026 1212068693
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 07/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321922
Principal investigator 1 PFIZER INC. $14,024.93 07/12/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228765285
Principal investigator 1 Janssen Research & Development, LLC $3,210.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175321036
Principal investigator 1 Janssen Research & Development, LLC $17,061.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175323086
Principal investigator 1 PFIZER INC. $23,747.63 06/25/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228777283
Principal investigator 1 PFIZER INC. $47,686.32 05/29/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228764401
Principal investigator 1 Janssen Research & Development, LLC $3,938.00 05/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175318991
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 05/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325035
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 05/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325834
Principal investigator 1 PFIZER INC. $39,070.15 05/03/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228723392
Principal investigator 1 Janssen Research & Development, LLC $16,900.00 04/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175324122
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 04/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175324638
Principal investigator 1 Janssen Research & Development, LLC $500.00 04/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1175325971
Principal investigator 1 AstraZeneca UK Limited $4,000.00 03/26/2025 Non-covered Recipient Entity
SWEDISH HEALTH SERVICES
a modular phase second,open label,multicentre study to assess efficacy and safety as monotherapy or in combination with antia cancer agents in patients with relapsed refractory peripheral t cell lymphoma or classical hodgkin lymphoma No dispute reported 06/30/2026 1185552351
Principal investigator 1 PFIZER INC. $43,964.48 03/21/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228787324
Principal investigator 1 Kite Pharma, Inc. $12,403.00 03/18/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) No dispute reported 06/30/2026 1212068564
Principal investigator 1 F. Hoffmann-La Roche AG $4,631.00 03/05/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Ph 1b of mosunetuzumab combined with lenalidomide in relapsed or refractory follicular lymphoma No dispute reported 06/30/2026 1211556449
Principal investigator 1 F. Hoffmann-La Roche AG $6,339.00 03/05/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Ph 1b of mosunetuzumab combined with lenalidomide in relapsed or refractory follicular lymphoma No dispute reported 06/30/2026 1211556457
Principal investigator 1 PFIZER INC. $3,511.59 03/01/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228788341
Principal investigator 1 Eli Lilly and Company $335,136.85 02/07/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) No dispute reported 06/30/2026 1187872353
Principal investigator 1 Eli Lilly and Company $2,234.64 01/27/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) No dispute reported 06/30/2026 1187877409
Principal investigator 1 Kite Pharma, Inc. $6,783.24 01/22/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7) No dispute reported 06/30/2026 1212068686
Principal investigator 1 PFIZER INC. $5,636.39 01/14/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION No dispute reported 06/30/2026 1228799869